# Core B: Biospecimen and Pathology Core

> **NIH NIH P50** · FRED HUTCHINSON CANCER RESEARCH CENTER · 2020 · $323,707

## Abstract

PROJECT SUMMARY/ABSTRACT
The Biospecimen and Pathology Core provides part of the infrastructure support for the major projects
comprising the Pacific Northwest Prostate Cancer SPORE as well as for research conducted through the
developmental research and career enhancement programs. It has been designed to meet the needs of these
projects and serve as a resource for collaborative efforts with other SPOREs. This Core will provide a systematic
and standardized system of specimen collection, storage, distribution and related clinical/research information
dissemination that is based on over two decades of experience. There will be consistency and quality assurance
in the pathological analysis of tissue specimens. This Core has 5 components:
1. Clinical specimen acquisition (i.e. tissues, including those from surgery and the rapid autopsy program,
 serum, plasma and urine), processing, quality control, storage, distribution and database entry;
2. A program to continually improve the quality and efficiency of biospecimen acquisition, processing and
 storage to increase the fidelity of specimens provided to the SPORE investigators;
3. Maintain prostate cancer xenograft lines established by the Core and make specimens available for biological
 study and/or perform pre-clinical studies for SPORE investigators and collaborators;
4. Laboratory services, including production of tissue microarrays, interpretation of immunohistology by urologic
 pathologists, production of specimen derivatives and perform PSA immunoassays for research;
5. An administrative program to obtain samples from minorities, prioritize the distribution of specimens, ensure
 patient confidentiality and compliance with IRB requirements, maintain and improve quality control measures
 and interact with other SPOREs.
Specimens from our repository, especially those from our rapid autopsy program (e.g. PC bone metastases) and
our LuCaP series of prostate cancer xenografts have been, and will continue to be distributed to other PC
investigators on an international basis.

## Key facts

- **NIH application ID:** 10016181
- **Project number:** 5P50CA097186-18
- **Recipient organization:** FRED HUTCHINSON CANCER RESEARCH CENTER
- **Principal Investigator:** Colm M Morrissey
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $323,707
- **Award type:** 5
- **Project period:** 2002-09-19 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10016181

## Citation

> US National Institutes of Health, RePORTER application 10016181, Core B: Biospecimen and Pathology Core (5P50CA097186-18). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10016181. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*